Filippo Greco

Dr. Filippo Greco


Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in Gynecologic Oncology
Verified
Journal Article
Open access
GAGrazia Artioli
Grazia Artioli
GGGAIA GIANNONE
GAIA GIANNONE
Giorgio ValabregaGiorgio Valabrega
Giorgio Valabrega
FMFurio Maggiorotto
Furio Maggiorotto
Sofia GentaSofia Genta
Sofia Genta
LBLucia Borgato
Lucia Borgato
Around 15% of epithelial ovarian cancer (EOC) patients (pts) harbor a germline BRCA1 or 2 mutation, showing different features than BRCA wild-type pts. The clinical and pathological features of an Italian BRCA mutated EOC cohort were described. We retrospectively analyzed clinical, pathological and mutational data from a cohort of Italian BRCA mutated EOC pts. treated in 15 MITO centers between 1995 and 2017. Three-hundred thirty-one pts. were recorded. Two-hundred forty (72%) and 91 (27.5%) pts. harbored a BRCA1 and BRCA2 mutation, respectively. Median age at diagnosis was 52 years. The most frequent diagnosis was a high grade serous FIGO III or IV EOC and platinum doublet in first-line was administered to almost all pts. Fifty-three % of them had no residual disease (R = 0) at surgery. Median progression-free-survival (mPFS) after first-line chemotherapy was 29 months. Expected percentage of pts. alive at 5 years was 72.5% (CI 60.2-80.8%) and R = 0 predicted a significantly longer overall survival (OS). Sixty-six pts. (19,9%) had both an EOC and a breast cancer (BC) diagnosis. The first diagnosis was BC in 81,8% of cases with a mean interval between the two diagnoses (IBTDs) of 132.4 months. Mutational data show that the founder mutation c.5266dupC in BRCA1 was the most frequently recorded. This is the largest Italian BRCA mutEOC cohort. The only predictor of longer OS was R = 0. EOC pts. that developed subsequently a BC are long-term survivors.

29 November 2018 in Pathology - Research and Practice
Verified
Journal Article
Closed access
PPpietro parcesepe
pietro parcesepe
GGGuido Giordano
Guido Giordano
CZCaterina Zanella
Caterina Zanella
Jacopo GiulianiJacopo Giuliani
Jacopo Giuliani
FGFilippo Greco
Filippo Greco
Andrea remoAndrea remo
Andrea remo

7 December 2024 in Cancers
Verified
Journal Article
Open access
PDF file
EKEriseld Krasniqi
Eriseld Krasniqi
LFLorena Filomeno
Lorena Filomeno
TATeresa Arcuri
Teresa Arcuri
FLFrancesca Sofia Di Lisa
Francesca Sofia Di Lisa
AAAntonio Astone
Antonio Astone
PVPatrizia Vici
Patrizia Vici
Background/Objectives: HER2-positive breast cancer (HER2+BC) is an aggressive subtype, with neoadjuvant treatment (NAT) aiming to achieve a pathological complete response (pCR) to improve long-term outcomes. Trastuzumab emtansine (T-DM1) has been established as the standard of care in the adjuvant setting for HER2+BC patients who do not obtain pCR. The ATD study aimed to evaluate the real-world tolerability of T-DM1 in this setting. The secondary objective was to assess the effectiveness. Methods: This was a multicenter, retrospective study across 24 Italian oncology centers, including 410 patients with HER2+BC treated with adjuvant T-DM1 following a lack of pCR after NAT. Patient characteristics, NAT regimens, and surgical outcomes were recorded. Tolerability was assessed by documenting adverse events (AEs) according to the CTCAE (v5.0). Preliminary effectiveness was evaluated in terms of relapse-free survival (RFS) and overall survival (OS). Results: Overall, 228 patients (55.6%) experienced at least one AE related to T-DM1, with 4.9% experiencing grade 3 or higher AEs. The most common AEs were hepatotoxicity (18.5%) and thrombocytopenia (17.6%). T-DM1 was discontinued in 10.0% of patients due to toxicity. After a median follow-up of 25 months, 31 relapse events (7.6%) and 22 deaths (5.4%) were reported. The preliminary incidence of RFS and OS events was similar between patients who completed the T-DM1 course and those who discontinued it early. Conclusions: T-DM1 demonstrated a manageable safety profile, and the adverse events were consistent with those reported in randomized trials. The data are not yet sufficient to allow for a formal analysis of RFS and OS, and long-term follow-up is required.

8 February 2014
Verified
Journal Article
Closed access
PPPaolo Piacentini
Paolo Piacentini
FGFilippo Greco
Filippo Greco
AMAnna Mercanti
Anna Mercanti
ATAnna Rita Trolese
Anna Rita Trolese
EDEmilia Durante
Emilia Durante
ABAndrea Bonetti
Andrea Bonetti

5 December 2025 in ESMO Open
Verified
Journal Article
Open access
MBMichele Bartoletti
Michele Bartoletti
APA. Passarelli
A. Passarelli
AFANNA FAGOTTI
ANNA FAGOTTI
CAC. Andreetta
C. Andreetta
STS. Tamberi
S. Tamberi
SPSandro Pignata
Sandro Pignata
Poly (ADP-ribose) polymerase (PARP) inhibitor use in endometrial cancer (EC) requires predictive biomarkers, currently lacking in clinical practice. This study assessed the incidence of homologous recombination deficiency (HRD) using genomic loss of heterozygosity (gLOH) and a machine learning-based HRD scar signature (HRDsig). MITO END 3 was a multicenter, phase II trial of advanced EC patients randomly assigned to receive platinum-based chemotherapy ± avelumab. Of 125 patients, 102 had tumor samples available for sequencing with FoundationOne®CDx. HRD was evaluated using gLOH (cut-off ≥16%, based on ARIEL3) and HRDsig (cut-off ≥0.7, validated pan-cancer). Among 102 evaluable samples, 5 were HRDsig-positive, 90 HRDsig-negative, and 7 HRDsig unknown. gLOH was high in 10 cases, low in 53, and not assessable in 39. Most HRDsig-positive (4/5) and gLOH-high (8/10) tumors were of endometrioid histology and carried TP53 mutations. None were microsatellite instability-high. A small subgroup of advanced EC patients shows HRD positivity by gLOH or HRDsig, potentially identifying those most likely to benefit from PARP inhibitors. These tumors are typically endometrioid with TP53 mutations.